{"format":"alysly-page/1","url":"https://alysly.com/markets/stocks/royalty-pharma-plc-class-a/","json":"https://alysly.com/json/markets/stocks/royalty-pharma-plc-class-a/index.json","lang":"en-US","title":"Royalty Pharma Plc Class A (RPRX) Stock Price Today | News","description":"Royalty Pharma Plc Class A (RPRX). Held in 20 ETFs (top 0.40% in XUHL). Revenue $2.4bn, net margin 32.4% (FY ended Dec 2025). ISIN GB00BMVP7Y09.","modified":"2026-11-02T00:00:00Z","alternates":[{"lang":"de-DE","url":"https://alysly.com/de/maerkte/aktien/royalty-pharma-plc-class-a/","json":"https://alysly.com/json/de/maerkte/aktien/royalty-pharma-plc-class-a/index.json"}],"about":"Machine-readable version of the page at url. It contains the text, tables and key figures published there, but not the interactive charts and tools.","breadcrumb":[{"name":"Markets","url":"https://alysly.com/markets/"},{"name":"Stocks","url":"https://alysly.com/markets/stocks/"},{"name":"Royalty Pharma Plc Class A","url":"https://alysly.com/markets/stocks/royalty-pharma-plc-class-a/"}],"content":[{"type":"heading","level":1,"text":"Royalty Pharma Plc Class A (RPRX)"},{"type":"paragraph","text":"RPRX · Health Care · United States","links":[{"text":"Health Care","href":"https://alysly.com/markets/stocks/browse/?sector=Health%20Care"},{"text":"United States","href":"https://alysly.com/markets/stocks/browse/?country=United%20States"}]},{"type":"paragraph","text":"Royalty Pharma Plc Class A (RPRX) is a US company in the Health Care sector. The stock has its largest weight in XUHL (MSCI USA Health Care), at 0.40%. Anyone who holds an ETF containing Royalty Pharma Plc also has an indirect stake in the company."},{"type":"heading","level":2,"id":"data","text":"Data and Charts: Royalty Pharma Plc"},{"type":"heading","level":3,"text":"Key Data for Royalty Pharma Plc"},{"type":"facts","items":[{"label":"Held in","value":"20 ETFs"},{"label":"Highest weight","value":"0.40%"},{"label":"Indices","value":"10"},{"label":"Sector","value":"Health Care"},{"label":"Country","value":"United States"},{"label":"ISIN","value":"GB00BMVP7Y09"}]},{"type":"paragraph","text":"Data note 1","href":"#dn-1"},{"type":"heading","level":3,"text":"Royalty Pharma Plc Stock Price Chart"},{"type":"paragraph","text":"The Royalty Pharma Plc chart shows daily closing prices and is set to the current year by default. The stock is up 73.9% year to date and up 81.9% over twelve months. The last recorded close on October 30, 2026, was $67.18, at 100% of the 52-week range."},{"type":"paragraph","text":"Price series from our database since Aug 12, 2024, 558 daily values."},{"type":"paragraph","text":"Data note 2","href":"#dn-2"},{"type":"heading","level":3,"text":"Royalty Pharma Plc Stock Performance"},{"type":"table","caption":"Royalty Pharma Plc stock performance","rows":[["Year to date","+73.9%","1 year","+81.9%"],["1 month","+15.1%","3 months","+15.0%"],["Calendar year 2025","+51.5%","",""]]},{"type":"paragraph","text":"Data note 3","href":"#dn-3"},{"type":"paragraph","text":"Measured in euros, Royalty Pharma Plc is up 82.9% year to date and up 88.0% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day."},{"type":"paragraph","text":"Data note 4","href":"#dn-4"},{"type":"heading","level":2,"id":"alysly","text":"Alysly Data Analysis: Royalty Pharma Plc"},{"type":"heading","level":3,"text":"What ETF Is Royalty Pharma Plc In?"},{"type":"paragraph","text":"Royalty Pharma Plc has above-average ETF coverage and is held by 20 of the 104 ETFs we track, which together follow 10 indices. That puts the stock in more ETFs than 80.9% of the 4,341 stocks we track.","links":[{"text":"4,341 stocks we track","href":"https://alysly.com/markets/stocks/"}]},{"type":"paragraph","text":"Data note 5","href":"#dn-5"},{"type":"table","caption":"What ETF is Royalty Pharma Plc in","columns":["ETF","Index","Weight","per €1,000 in the ETF"],"rows":[[{"text":"XUHL / XUHC","links":[{"text":"XUHL","href":"https://alysly.com/markets/etfs/xtrackers-msci-usa-health-care-ucits-etf-1c/"}]},{"text":"MSCI USA Health Care","href":"https://alysly.com/markets/indices/msci-usa-health-care/"},"0.40%","€4.03"],[{"text":"SPFS","href":"https://alysly.com/markets/etfs/state-street-spdr-msci-world-health-care-ucits-etf/"},{"text":"MSCI World Health Care","href":"https://alysly.com/markets/indices/msci-world-health-care/"},"0.30%","€3.00"],[{"text":"XDWH","href":"https://alysly.com/markets/etfs/xtrackers-msci-world-health-care-ucits-etf-1c/"},{"text":"MSCI World Health Care","href":"https://alysly.com/markets/indices/msci-world-health-care/"},"0.30%","€2.98"],[{"text":"XDEV","href":"https://alysly.com/markets/etfs/xtrackers-msci-world-value-ucits-etf-1c/"},{"text":"MSCI World Value","href":"https://alysly.com/markets/indices/msci-world-value/"},"0.17%","€1.70"],[{"text":"XDEM","href":"https://alysly.com/markets/etfs/xtrackers-msci-world-momentum-ucits-etf-1c/"},{"text":"MSCI World Momentum","href":"https://alysly.com/markets/indices/msci-world-momentum/"},"0.14%","€1.40"],[{"text":"2B7K","href":"https://alysly.com/markets/etfs/ishares-msci-world-sri-ucits-etf-eur-acc/"},{"text":"MSCI World SRI","href":"https://alysly.com/markets/indices/msci-world-sri/"},"0.13%","€1.30"],[{"text":"WVAL","href":"https://alysly.com/markets/etfs/state-street-spdr-msci-world-value-ucits-etf-acc/"},{"text":"MSCI World Value","href":"https://alysly.com/markets/indices/msci-world-value/"},"0.10%","€1.02"],[{"text":"XD9U / XD9D","links":[{"text":"XD9U","href":"https://alysly.com/markets/etfs/xtrackers-msci-usa-ucits-etf-1c/"}]},{"text":"MSCI USA","href":"https://alysly.com/markets/indices/msci-usa/"},"0.04%","€0.41"],[{"text":"SWWD","href":"https://alysly.com/markets/etfs/state-street-spdr-msci-world-ucits-etf-dist/"},{"text":"MSCI World","href":"https://alysly.com/markets/indices/msci-world/"},"0.04%","€0.40"],[{"text":"SPPW","href":"https://alysly.com/markets/etfs/spdr-msci-world-ucits-etf/"},{"text":"MSCI World","href":"https://alysly.com/markets/indices/msci-world/"},"0.04%","€0.40"],[{"text":"EUNL","href":"https://alysly.com/markets/etfs/ishares-core-msci-world-ucits-etf-usd-acc/"},{"text":"MSCI World","href":"https://alysly.com/markets/indices/msci-world/"},"0.03%","€0.30"],[{"text":"XDWD / XDWL","links":[{"text":"XDWD","href":"https://alysly.com/markets/etfs/xtrackers-msci-world-ucits-etf-1c/"}]},{"text":"MSCI World","href":"https://alysly.com/markets/indices/msci-world/"},"0.03%","€0.30"],[{"text":"WIMI","href":"https://alysly.com/markets/etfs/xtrackers-msci-world-imi-ucits-etf-1c/"},{"text":"MSCI World IMI","href":"https://alysly.com/markets/indices/msci-world-imi/"},"0.03%","€0.27"],[{"text":"SPYY","href":"https://alysly.com/markets/etfs/state-street-spdr-msci-all-country-world-ucits-etf-acc/"},{"text":"MSCI ACWI","href":"https://alysly.com/markets/indices/msci-acwi/"},"0.03%","€0.25"],[{"text":"IUSQ","href":"https://alysly.com/markets/etfs/ishares-msci-acwi-ucits-etf-usd-acc/"},{"text":"MSCI ACWI","href":"https://alysly.com/markets/indices/msci-acwi/"},"0.02%","€0.20"],[{"text":"SPYI / SPSA","links":[{"text":"SPYI","href":"https://alysly.com/markets/etfs/state-street-spdr-msci-all-country-world-investable-market-ucits-etf-acc/"}]},{"text":"MSCI ACWI IMI","href":"https://alysly.com/markets/indices/msci-acwi-imi/"},"0.01%","€0.07"]]},{"type":"paragraph","text":"Data note 6","href":"#dn-6"},{"type":"paragraph","text":"The last column shows how much of €1,000 in one of these funds goes to Royalty Pharma Plc, based on each fund's latest holdings list."},{"type":"paragraph","text":"US-listed ETFs holding Royalty Pharma Plc (weight per latest SEC filing): VYM 0.10%, ONEQ 0.05%. These funds are registered in the US; retail investors in the EU usually cannot buy them.","links":[{"text":"VYM","href":"https://alysly.com/markets/etfs/us/vym/"},{"text":"ONEQ","href":"https://alysly.com/markets/etfs/us/oneq/"}]},{"type":"list","ordered":false,"items":[{"text":"Royalty Pharma Plc among the 4,341 stocks we track","href":"https://alysly.com/markets/stocks/etf-concentration/"},{"text":"Check the overlap of these 20 funds","href":"https://alysly.com/markets/etfs/overlap/"}]},{"type":"heading","level":3,"text":"Royalty Pharma Plc Weight in iShares Core MSCI World (EUNL) Since 2020"},{"type":"image","alt":"Royalty Pharma Plc: weight in EUNL 0.01% → 0.03%"},{"type":"paragraph","text":"Dec 31, 2020 Oct 30, 2026"},{"type":"paragraph","text":"In iShares Core MSCI World (EUNL), Royalty Pharma Plc had a weight of 0.01% on Dec 31, 2020 and 0.03% on Oct 30, 2026. The fund tracks the MSCI World. Its share peaked at 0.03% on Jun 30, 2022. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.","links":[{"text":"iShares Core MSCI World (EUNL)","href":"https://alysly.com/markets/etfs/ishares-core-msci-world-ucits-etf-usd-acc/"},{"text":"MSCI World","href":"https://alysly.com/markets/indices/msci-world/"}]},{"type":"paragraph","text":"Data note 7","href":"#dn-7"},{"type":"paragraph","text":"What's Inside Your ETF Portfolio and the ETF overlap check show how much Royalty Pharma Plc overlaps with the rest of a portfolio.","links":[{"text":"What's Inside Your ETF Portfolio","href":"https://alysly.com/tools/portfolio-xray/"},{"text":"ETF overlap check","href":"https://alysly.com/tools/etf-overlap/"}]},{"type":"heading","level":3,"text":"What Royalty Pharma Plc Executives and Directors Traded Recently"},{"type":"table","caption":"Trades by executives and directors","columns":["Date","Person","Type","Shares","Price"],"rows":[["Oct 5, 2026","Urist Marshall Officer, EVP, Research & Investments","Sell (plan)","4,126","$57.10"],["Sep 28, 2026","Urist Marshall Officer, EVP, Research & Investments","Sell (plan)","4,126","$57.88"],["Sep 22, 2026","Hite Christopher Officer, EVP & Chairman, Partnering","Sell (plan)","3,927","$58.93"],["Sep 22, 2026","Hite Christopher Officer, EVP & Chairman, Partnering","Sell (plan)","96,073","$58.51"]]},{"type":"paragraph","text":"The table shows open-market purchases and sales reported over the past 90 days. Directors, officers and shareholders owning more than ten percent must report such transactions within two trading days. Awards and option exercises are excluded."},{"type":"paragraph","text":"“Plan” means the transaction follows a schedule set up in advance under Rule 10b5-1. Sales consistently outnumber purchases in these filings because a large part of executive pay is granted in shares. For comparison: over the period covered, executives and directors reported sales at 271 of 350 tracked companies and purchases at 32."},{"type":"paragraph","text":"Data note 8","href":"#dn-8"},{"type":"heading","level":3,"text":"Stocks With ETF Exposure Similar to Royalty Pharma Plc"},{"type":"table","caption":"Stocks with ETF exposure similar to Royalty Pharma Plc","columns":["Stock","Shared ETFs","r","1 year","Annualized volatility","Net margin","Revenue growth"],"rows":[["Royalty Pharma Plc","–","–","+81.9%","23.4%","32.4%","+5.1%"],[{"text":"Roivant Sciences","href":"https://alysly.com/markets/stocks/roivant-sciences-ltd/"},"17","–","+88.5%","39.4%","-3,629.2%","-71.6%"],[{"text":"Revolution Medicines","href":"https://alysly.com/markets/stocks/revolution-medicines-inc/"},"17","–","+225.0%","56.2%","–","–"],[{"text":"Biogen","href":"https://alysly.com/markets/stocks/biogen-inc/"},"20","–","+69.5%","32.1%","13.1%","+2.2%"],[{"text":"United Therapeutics Corporation","href":"https://alysly.com/markets/stocks/united-therapeutics-corporation/"},"18","–","+32.0%","41.2%","41.9%","+10.6%"],[{"text":"Centene Corporation","href":"https://alysly.com/markets/stocks/centene-corporation/"},"20","–","+95.5%","50.4%","-3.4%","+19.4%"],[{"text":"Insmed Incorporated","href":"https://alysly.com/markets/stocks/insmed-incorporated/"},"16","–","-42.0%","54.9%","-210.5%","+66.7%"],[{"text":"Medline","href":"https://alysly.com/markets/stocks/medline-inc-class-a/"},"16","–","–","43.8%","4.1%","+11.5%"],[{"text":"Natera","href":"https://alysly.com/markets/stocks/natera-inc/"},"16","–","+114.4%","46.7%","-9.0%","+35.9%"]]},{"type":"paragraph","text":"These stocks reach a portfolio through largely the same funds as Royalty Pharma Plc. “Shared ETFs” counts the funds that hold both."},{"type":"paragraph","text":"Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical."},{"type":"paragraph","text":"Data note 9","href":"#dn-9"},{"type":"heading","level":2,"id":"fundamental","text":"Fundamental Analysis: Royalty Pharma Plc"},{"type":"heading","level":3,"text":"Royalty Pharma Plc Key Financials"},{"type":"facts","items":[{"label":"Revenue","value":"$2.4B"},{"label":"Net income","value":"$770.9M"},{"label":"Diluted EPS","value":"$1.78"},{"label":"Net margin","value":"32.4%"},{"label":"Revenue growth","value":"+5.1%"}]},{"type":"paragraph","text":"Figures come from the SEC annual filing for the latest reported fiscal year (period end Dec 31, 2025)."},{"type":"table","caption":"Revenue and profit by fiscal year","columns":["Fiscal year","Revenue","Net income","Margin"],"rows":[["FY ended Dec 2023","2.4","1.1","48.2%"],["FY ended Dec 2024","2.3","0.9","37.9%"],["FY ended Dec 2025","2.4","0.8","32.4%"]]},{"type":"paragraph","text":"Data note 10","href":"#dn-10"},{"type":"heading","level":2,"id":"technical","text":"Technical Analysis: Royalty Pharma Plc"},{"type":"heading","level":3,"text":"Royalty Pharma Plc Risk Metrics"},{"type":"facts","items":[{"label":"Max drawdown","value":"-17.0%"},{"label":"Annualized volatility","value":"23.4%"}]},{"type":"paragraph","text":"Data note 11","href":"#dn-11"},{"type":"facts","items":[{"label":"Below peak","value":"0.0%"},{"label":"Beta to S&P 500","value":"0.20"},{"label":"Correlation to S&P 500","value":"0.11"}]},{"type":"paragraph","text":"The close on Oct 30, 2026, was the highest since our series began on Aug 12, 2024. When the S&P 500 rose or fell 1%, Royalty Pharma Plc moved 0.20% on average in the same direction (past 252 trading days). The correlation of 0.11, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of Royalty Pharma Plc."},{"type":"paragraph","text":"Data note 12","href":"#dn-12"},{"type":"heading","level":3,"text":"What Royalty Pharma Plc Correlates With"},{"type":"table","caption":"What Royalty Pharma Plc Correlates With","columns":["Instrument","r","−1 … +1"],"rows":[[{"text":"Amgen Inc.","href":"https://alysly.com/markets/stocks/amgen-inc/"},"+0.72",""],[{"text":"AbbVie Inc.","href":"https://alysly.com/markets/stocks/abbvie-inc/"},"+0.65",""],[{"text":"Gilead Sciences Inc.","href":"https://alysly.com/markets/stocks/gilead-sciences-inc/"},"+0.64",""],[{"text":"Eli Lilly and Company","href":"https://alysly.com/markets/stocks/eli-lilly-and-company/"},"+0.63",""],[{"text":"Bristol-Myers Squibb Company","href":"https://alysly.com/markets/stocks/bristol-myers-squibb-company/"},"+0.62",""],[{"text":"Vertex Pharmaceuticals Incorporated","href":"https://alysly.com/markets/stocks/vertex-pharmaceuticals-incorporated/"},"+0.62",""],[{"text":"YB","href":"https://alysly.com/markets/crypto/yb/"},"-0.43",""],[{"text":"Eaton Corp. Plc","href":"https://alysly.com/markets/stocks/eaton-corp-plc/"},"-0.38",""],[{"text":"nVent Electric plc","href":"https://alysly.com/markets/stocks/nvent-electric-plc/"},"-0.38",""]]},{"type":"paragraph","text":"The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio."},{"type":"paragraph","text":"Data note 13","href":"#dn-13"},{"type":"heading","level":2,"id":"refs","text":"Related Content: Royalty Pharma Plc"},{"type":"heading","level":3,"text":"Latest Investment Analysis: Stocks"},{"type":"list","ordered":false,"items":[{"text":"Oct 31, 2026 · Mixed Weekly Analysis: DAX Sets the Tone for the Week (+2.2%) · October 26–30, 2026","href":"https://alysly.com/analysis/weekly-analysis-dax-sets-tone-week-plus-2-2-percent-10312026/"},{"text":"Oct 24, 2026 · Risk-off Weekly Analysis: A Quiet Week, MSCI China -4.3% · October 19–23, 2026","href":"https://alysly.com/analysis/weekly-analysis-quiet-week-msci-china-minus-4-3-percent-10242026/"},{"text":"Oct 17, 2026 · Risk-off Weekly Analysis: S&P 500 Information Technology Weighs on the Week (-7.7%) · October 12–16, 2026","href":"https://alysly.com/analysis/weekly-analysis-sp-500-information-technology-weighs-week-10172026/"}]},{"type":"paragraph","text":"View all Investment Analysis","href":"https://alysly.com/analysis/"},{"type":"paragraph","text":"Updated Nov 2, 2026"},{"type":"heading","level":2,"id":"note-legend-h","text":"Data Notes"},{"type":"paragraph","text":"All calculations run automatically and are not investment advice."},{"type":"list","ordered":true,"items":[{"id":"dn-1","text":"Number of ETFs with available holdings data that hold the stock; the percentile compares all covered stocks against that same set."},{"id":"dn-2","text":"Price history from daily closing prices; one point per trading day."},{"id":"dn-3","text":"Returns computed automatically from the price series, excluding dividends, taxes and costs."},{"id":"dn-4","text":"Daily dollar prices converted at the same day's ECB euro reference rate, then measured like the dollar return."},{"id":"dn-5","text":"We count the funds we cover, not the market; the history covers the funds whose holdings reach back monthly."},{"id":"dn-6","text":"Holdings as of the fund's latest published holdings list; the as-of date is shown at the block."},{"id":"dn-7","text":"From the fund's published holdings lists at each quarter end, plus the latest date."},{"id":"dn-8","text":"Purchases and sales by directors, officers and ten-percent owners from Form 4 filings with the US securities regulator, reported two trading days after the transaction."},{"id":"dn-9","text":"Selected by how many of the funds we track hold both names, not by business model."},{"id":"dn-10","text":"Latest reported fiscal year from XBRL annual filings with the SEC (public domain), figures in billions of US dollars; ratios computed from them."},{"id":"dn-11","text":"Computed from the full available price history."},{"id":"dn-12","text":"From daily closes: distance from the series' highest close; beta and correlation of daily returns to the S&P 500 over the last 252 trading days."},{"id":"dn-13","text":"Co-movement of daily returns over the last 90 trading days, across asset classes."}]},{"type":"paragraph","text":"Data and methodology: Alysly · Responsible for content: Alexander Bock","links":[{"text":"Alysly","href":"https://alysly.com/methodology/"},{"text":"Alexander Bock","href":"https://alysly.com/about/"}]},{"type":"paragraph","text":"View all data notes","href":"https://alysly.com/notes/"}],"structured_data":[{"@context":"https://schema.org","@graph":[{"@type":"Organization","@id":"https://alysly.com/#org","name":"Alysly","url":"https://alysly.com/","logo":{"@type":"ImageObject","url":"https://alysly.com/img/icon-512.png","width":512,"height":512},"description":"Data-driven insights, transparent analysis and powerful tools for long-term investors.","email":"mail@alysly.com","contactPoint":{"@type":"ContactPoint","contactType":"customer support","email":"mail@alysly.com","availableLanguage":["de","en"]},"address":{"@type":"PostalAddress","addressLocality":"Haltern am See","postalCode":"45721","addressCountry":"DE"},"founder":{"@id":"https://alysly.com/#founder"},"sameAs":["https://www.linkedin.com/company/alyslycom/","https://www.youtube.com/@alyslycom","https://x.com/alyslycom"],"publishingPrinciples":"https://alysly.com/methodology/"},{"@type":"Person","@id":"https://alysly.com/#founder","name":"Alexander Bock","jobTitle":"Founder and data analyst","url":"https://alysly.com/about/","sameAs":["https://www.linkedin.com/in/abxk/"]},{"@type":"WebSite","@id":"https://alysly.com/#site","url":"https://alysly.com/","name":"Alysly","alternateName":"Alysly Investment Analysis","inLanguage":"en-US","publisher":{"@id":"https://alysly.com/#org"},"potentialAction":{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://alysly.com/markets/stocks/browse/?q={search_term_string}"},"query-input":"required name=search_term_string"}},{"@type":"WebPage","@id":"https://alysly.com/markets/stocks/royalty-pharma-plc-class-a/#webpage","url":"https://alysly.com/markets/stocks/royalty-pharma-plc-class-a/","name":"Royalty Pharma Plc Class A – Alysly","description":"Royalty Pharma Plc Class A (RPRX). Held in 20 ETFs (top 0.40% in XUHL). Revenue $2.4bn, net margin 32.4% (FY ended Dec 2025). ISIN GB00BMVP7Y09.","inLanguage":"en-US","isPartOf":{"@id":"https://alysly.com/#site"},"dateModified":"2026-11-02T00:00:00Z","publisher":{"@id":"https://alysly.com/#org"},"mainEntity":{"@id":"https://alysly.com/markets/stocks/royalty-pharma-plc-class-a/#entity"},"primaryImageOfPage":{"@type":"ImageObject","url":"https://alysly.com/og.png","width":1200,"height":630}}]},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Markets","item":"https://alysly.com/markets/"},{"@type":"ListItem","position":2,"name":"Stocks","item":"https://alysly.com/markets/stocks/"},{"@type":"ListItem","position":3,"name":"Royalty Pharma Plc Class A"}]},{"@context":"https://schema.org","@type":"Corporation","@id":"https://alysly.com/markets/stocks/royalty-pharma-plc-class-a/#entity","name":"Royalty Pharma Plc Class A","tickerSymbol":"RPRX","url":"https://alysly.com/markets/stocks/royalty-pharma-plc-class-a/","mainEntityOfPage":"https://alysly.com/markets/stocks/royalty-pharma-plc-class-a/","description":"Royalty Pharma Plc Class A (RPRX). Held in 20 ETFs (top 0.40% in XUHL). Revenue $2.4bn, net margin 32.4% (FY ended Dec 2025). ISIN GB00BMVP7Y09.","logo":"https://alysly.com/stock-logos/royalty-pharma-plc-logo.webp","image":"https://alysly.com/stock-logos/royalty-pharma-plc-logo.webp","identifier":[{"@type":"PropertyValue","propertyID":"TICKER","value":"RPRX"},{"@type":"PropertyValue","propertyID":"ISIN","value":"GB00BMVP7Y09"}],"address":{"@type":"PostalAddress","addressCountry":"US"},"subjectOf":{"@type":"Dataset","name":"Royalty Pharma Plc Class A — key figures","url":"https://alysly.com/markets/stocks/royalty-pharma-plc-class-a/","description":"Royalty Pharma Plc Class A (RPRX). Held in 20 ETFs (top 0.40% in XUHL). Revenue $2.4bn, net margin 32.4% (FY ended Dec 2025). ISIN GB00BMVP7Y09.","inLanguage":"en-US","isAccessibleForFree":true,"creator":{"@id":"https://alysly.com/#org"},"publisher":{"@id":"https://alysly.com/#org"},"variableMeasured":[{"@type":"PropertyValue","name":"Held in ETFs","value":20},{"@type":"PropertyValue","name":"Highest ETF weight (%)","value":0.4026},{"@type":"PropertyValue","name":"YTD return (%)","value":73.9},{"@type":"PropertyValue","name":"1-year return (%)","value":81.9},{"@type":"PropertyValue","name":"Sector","value":"Health Care"},{"@type":"PropertyValue","name":"Revenue (USD)","unitText":"USD","value":2378193000.0},{"@type":"PropertyValue","name":"Net income (USD)","unitText":"USD","value":770947000.0},{"@type":"PropertyValue","name":"Total assets (USD)","unitText":"USD","value":19620780000.0},{"@type":"PropertyValue","name":"Diluted EPS (USD)","value":1.78},{"@type":"PropertyValue","name":"Net margin (%)","value":32.4},{"@type":"PropertyValue","name":"Fiscal year end","value":"2025-12-31"}],"temporalCoverage":"2024-08-12/.."}}],"notice":"© 2026 Alysly.com. Not investment advice. All data without guarantee. Financial information is analyzed and presented partly with AI assistance."}